| Autor: |
Menchicchi B; Institute of Plant Biology and Biotechnology (IBBP), University of Münster, Schlossplatz 8, D-48143 Münster, Germany.; Department of Medicine 1, University of Erlangen-Nüremberg, D-91054 Erlangen, Germany., Savvaidou E; Institute of Plant Biology and Biotechnology (IBBP), University of Münster, Schlossplatz 8, D-48143 Münster, Germany., Thöle C; Institute for Pharmaceutical Biology and Phytochemistry (IPBP), University of Münster, Correnstrasse 48, D-48149 Münster, Germany., Hensel A; Institute for Pharmaceutical Biology and Phytochemistry (IPBP), University of Münster, Correnstrasse 48, D-48149 Münster, Germany., Goycoolea FM; Institute of Plant Biology and Biotechnology (IBBP), University of Münster, Schlossplatz 8, D-48143 Münster, Germany.; School of Food Science and Nutrition, University of Leeds, LS2 9JT Leeds, United Kingdom. |
| Abstrakt: |
The Gram-negative bacterium Helicobacter pylori is the most common bacterial pathogen in humans, infecting 24-79% of the population at any time. Standard eradication protocols involve multi-target therapy including combinations of antibiotics, which has promoted the emergence of resistant strains. To address this challenge, we prepared antibiotic-free colloidal nanoparticles designed to interfere with the adhesion mechanisms of H. pylori and thus prevent both the onset and recurrence of infection. Our colloidal particles comprised a nanocapsule (NC) formulation based on an oil-core nanoemulsion co-stabilized with lysozyme and lecithin, coated with negatively charged low-molecular-weight (DexS40-NC) or high-molecular-weight (DexS500-NC) dextran sulfate, or positively charged chitosan (CS HMC+30 -NC). The oil core of all NC formulations was also loaded with curcumin, a model lipophilic phytochemical substance with well-documented anti-inflammatory and anti-tumor activities. Our proof-of-principle experiments showed that the DexS40-NC formulation inhibited the adhesion of H. pylori to AGS stomach cells in a dose-dependent manner. DexS40-NC achieved more potent inhibition than DexS500-NC or uncoated control nanoemulsions, whereas the effect of CS HMC+30 -NC was not clear-cut given the ability of this formulation to aggregate bacteria. DexS40-NC, unlike DexS500-NC, showed no cytotoxic effects against AGS, Caco-2, or MDCK cell lines. DexS40-NC is, therefore, a promising candidate for further development as an alternative or complementary therapy against H. pylori infections. |
